Herpes Simplex Virus 2 Infection Models

Herpes simplex virus 2 (HSV-2) is one of the most common sexually transmitted infections worldwide, affecting an estimated almost 500 million people globally. Unlike HSV-1, which spreads primarily through oral contact and causes orolabial as well as genital disease, HSV-2 is almost exclusively sexually transmitted and its disease is concentrated in the anogenital region.

The virus establishes lifelong latency in the sacral ganglia and reactivates to cause recurrent genital outbreaks — more frequently than HSV-1 does in genital infection — and between episodes it sheds asymptomatically from the skin and mucosa, which is responsible for most onward transmission. This asymptomatic shedding is what makes HSV-2 so difficult to control: most infected people don’t know they carry it, and most transmission comes from people with no visible symptoms.

The most severe acute disease occurs in two populations: neonates exposed to the virus during delivery through an infected birth canal, in whom disseminated or CNS infection carries high mortality; and immunocompromised individuals, who can develop severe, persistent, and treatment-resistant disease. There is no cure, no licensed vaccine, and an emerging problem of antiviral-resistant infection in the most vulnerable patients. TransPharm Preclinical Solutions can develop and validate a custom HSV-2 infection model to a program’s specifications.

The scientific problem in an HSV-2 program centers on the full disease cycle rather than on a single acute event. The disease has three distinct phases that each demand different things from a model and a candidate: the primary genital infection, the pattern of periodic recurrence driven by reactivation from sacral ganglia, and the persistent asymptomatic shedding that drives transmission. A candidate aimed at clearing primary infection answers a different question than one aimed at suppressing recurrence or reducing shedding, and only one of those questions directly addresses the transmission problem.

A susceptible reference strain supports acute and recurrence studies, while an acyclovir-resistant isolate is the appropriate challenge for a program aimed at the immunocompromised patients in whom resistance emerges under prolonged therapy. Because there is no off-the-shelf validated HSV-2 model on the current platform, the model format, host, strain, and endpoints are defined together at the outset of a program. TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized HSV-2 isolates to a program’s specifications.

HSV-2 is validated on request rather than as a fixed model. Its principal clinical presentations align with TransPharm Preclinical Solutions’ established platform — a genital infection model for primary and recurrent genital disease, and systemic models for the disseminated disease that occurs in neonates and immunocompromised patients. Any of these can be developed and validated, with challenge strain, host species and strain, route of administration, comparators, dosing, and endpoints configured to the program.

Because HSV-2 is a virus rather than a bacterium, the core readouts are virological — lesion severity scoring, viral shedding, and tissue viral burden, rather than CFU — with survival and pharmacokinetic profiling where applicable, and blood chemistry, additional tissue harvests, and histopathology available as add-ons. Contact TransPharm Preclinical Solutions to scope a study design suited to your candidate.

HSV-2 is treated with the same nucleoside analogues used for HSV-1 — acyclovir, valacyclovir, and famciclovir — all of which require activation by the viral thymidine kinase (TK). The resistance mechanisms are also identical: mutations in UL23 (which encodes TK) account for 95% of resistant isolates, abolishing or altering TK activity and preventing drug activation, with cross-resistance to other TK-dependent antivirals; mutations in UL30 (viral DNA polymerase) account for most of the remainder.

In immunocompetent people, acyclovir-resistant HSV-2 is rare. In the immunocompromised, particularly transplant recipients on prolonged suppressive therapy, it is a genuine therapeutic problem, and foscarnet or cidofovir — agents that don’t require TK activation — are the alternatives of last resort. Because the asymptomatic shedding that drives HSV-2 transmission is not reliably suppressed even by optimal antiviral therapy, and because no vaccine has reached licensure despite extensive development efforts, the development case extends beyond resistance to better agents for viral control, transmission prevention, and recurrence suppression.